- Home
- NGNE vs THRD Comparison
NGNE vs THRD Comparison
Compare NGNE & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- THRD
- Stock Information
- Founded
- NGNE 2003
- THRD 2019
- Country
- NGNE United States
- THRD United States
- Employees
- NGNE N/A
- THRD N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- THRD Health Care
- Exchange
- NGNE Nasdaq
- THRD Nasdaq
- Market Cap
- NGNE 471.1M
- THRD 513.2M
- IPO Year
- NGNE N/A
- THRD 2022
- Fundamental
- Price
- NGNE $15.59
- THRD $11.45
- Analyst Decision
- NGNE Strong Buy
- THRD Strong Buy
- Analyst Count
- NGNE 6
- THRD 3
- Target Price
- NGNE $60.80
- THRD $20.33
- AVG Volume (30 Days)
- NGNE 539.5K
- THRD 218.2K
- Earning Date
- NGNE 11-18-2024
- THRD 11-07-2024
- Dividend Yield
- NGNE N/A
- THRD N/A
- EPS Growth
- NGNE N/A
- THRD N/A
- EPS
- NGNE N/A
- THRD N/A
- Revenue
- NGNE $925,000.00
- THRD N/A
- Revenue This Year
- NGNE N/A
- THRD N/A
- Revenue Next Year
- NGNE N/A
- THRD N/A
- P/E Ratio
- NGNE N/A
- THRD N/A
- Revenue Growth
- NGNE N/A
- THRD N/A
- 52 Week Low
- NGNE $12.49
- THRD $7.08
- 52 Week High
- NGNE $74.49
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- NGNE 26.51
- THRD 40.06
- Support Level
- NGNE $35.60
- THRD $10.10
- Resistance Level
- NGNE $43.24
- THRD $12.49
- Average True Range (ATR)
- NGNE 6.30
- THRD 1.30
- MACD
- NGNE -5.15
- THRD -0.32
- Stochastic Oscillator
- NGNE 1.85
- THRD 25.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.